Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Secondary analyses comparing Hospitalizations for musculoskeletal conditions among DMARDs users and non-users before and after the introduction of anti-TNF drugs to the Quebec market

From: Hospitalization for musculoskeletal disorders in rheumatoid arthritis patients: a population-based study

  Exposure duration (days) Number (Unadjusted rate per 100 patient-yrs) Hazard ratio
(95 % CI)
  Total Median
(Quartile range)
1998–2001     
DMARDs 1,243,393 365.0 (12.0) 229 (6.72) 1.16 (0.95, 1.41)
Non-users 1,998,164 317.0 (193.0) 362 (6.61) 1.00 (Reference)
2002–2006     
DMARDs 1,949,824 365.0 (0.0) 289 (5.41) 0.86 (0.73, 1.01)
Non-users 3,270,739 365.0 (169.0) 614 (6.85) 1.00 (Reference)
2007–2011     
DMARDs 2,785,950 365.0 (0.0) 344 (4.51) 0.71 (0.60, 0.84)
Non-users 3,970,012 296.0 (224.0) 797 (7.33) 1.00 (Reference)
  1. CI confidence interval